Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 8;30(3):664–678. doi: 10.1111/bpa.12837

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Example staining patterns for molecular subgrouping medulloblastoma using the panel of YAP1, GAB1, and beta‐catenin. WNT‐activated medulloblastomas typically demonstrate immunoreactivity for YAP1, but are immunonegative for GAB1. Immunoreactivity for beta‐catenin is positive in both the cytoplasm and nucleus of WNT‐activated tumors (top panels). SHH‐activated medulloblastomas are immunoreactive for YAP1 and GAB1, but show reactivity for beta‐catenin that is restricted to the cytoplasm (middle panels). Non‐WNT/non‐SHH medulloblastomas show no immunoreactivity for YAP1 or GAB1, and immunoreactivity for beta‐catenin that is restricted to the cytoplasm only (bottom panels).